Omeros (OMER) Competitors $3.36 -0.12 (-3.45%) Closing price 04:00 PM EasternExtended Trading$3.50 +0.14 (+4.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OMER vs. NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTSShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Its Competitors Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Which has more risk and volatility, OMER or NKTR? Omeros has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Do institutionals & insiders believe in OMER or NKTR? 48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 5.3% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is OMER or NKTR more profitable? Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -152.49%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -59.68% Nektar Therapeutics -152.49%-329.54%-55.24% Do analysts recommend OMER or NKTR? Omeros currently has a consensus price target of $18.00, indicating a potential upside of 435.71%. Nektar Therapeutics has a consensus price target of $88.33, indicating a potential upside of 254.18%. Given Omeros' higher possible upside, research analysts plainly believe Omeros is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media prefer OMER or NKTR? In the previous week, Nektar Therapeutics had 3 more articles in the media than Omeros. MarketBeat recorded 8 mentions for Nektar Therapeutics and 5 mentions for Omeros. Omeros' average media sentiment score of 1.12 beat Nektar Therapeutics' score of 0.58 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, OMER or NKTR? Nektar Therapeutics has higher revenue and earnings than Omeros. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$156.82M-$2.65-1.27Nektar Therapeutics$98.43M3.14-$118.96M-$9.60-2.60 SummaryOmeros beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks. Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.90M$10.25B$5.54B$9.41BDividend YieldN/A2.06%3.75%4.03%P/E Ratio-1.2716.5828.0119.82Price / SalesN/A30.02433.8198.96Price / CashN/A22.3936.1658.27Price / Book-1.073.578.125.65Net Income-$156.82M$235.43M$3.25B$257.91M7 Day Performance-7.95%-1.67%0.97%2.09%1 Month Performance4.35%2.91%7.36%11.13%1 Year Performance-31.15%-16.44%31.31%18.40% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.7837 of 5 stars$3.36-3.4%$18.00+435.7%-33.1%$203.90MN/A-1.27210Positive NewsAnalyst RevisionGap UpNKTRNektar Therapeutics4.0618 of 5 stars$24.41-2.4%$88.33+261.9%+22.6%$302.86M$87.25M-2.54220Analyst RevisionASMBAssembly Biosciences3.7919 of 5 stars$18.84+0.5%$33.00+75.2%+27.1%$143.90M$32.15M-3.02100Trending NewsCPIXCumberland Pharmaceuticals0.8866 of 5 stars$3.40+13.3%N/A+152.4%$50.87M$41.08M-13.6080Trending NewsLLYEli Lilly and Company4.9798 of 5 stars$799.51+0.8%$1,012.56+26.6%-15.8%$757.72B$49.00B65.0547,000Trending NewsJNJJohnson & Johnson4.7823 of 5 stars$156.91+0.0%$171.00+9.0%+4.1%$377.55B$89.33B17.45138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionABBVAbbVie4.7836 of 5 stars$191.54-0.5%$211.29+10.3%+9.1%$338.33B$56.33B81.5055,000Trending NewsEx-DividendAnalyst RevisionMRKMerck & Co., Inc.4.9955 of 5 stars$83.72+0.4%$108.69+29.8%-35.2%$210.21B$64.17B12.1975,000Positive NewsPFEPfizer4.9618 of 5 stars$25.36-1.2%$28.55+12.6%-18.1%$144.15B$62.46B18.3781,000Trending NewsBMYBristol Myers Squibb4.8944 of 5 stars$47.36+1.1%$57.69+21.8%+11.4%$96.38B$47.64B17.7434,100Trending NewsAnalyst RevisionZTSZoetis4.9604 of 5 stars$155.68+0.5%$212.13+36.3%-17.6%$69.31B$9.26B27.9513,800Trending NewsAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMER) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
